Equity Research Available: Chemaphor Research Library

Chemaphor Inc. (TSX-V: CFR) is a biotechnology company operating in the animal and human health marketplaces. Its proprietary products are designed to provide improvements in health for pets (dogs, cats & horses) and, eventually, humans. The Company currently sells its products, i.e., Oximunol™ Chewable Tablets and its in-licensed Vet-Stem™ Regenerative Cell Therapy, to consumers through the veterinary clinic channel.

However, Chemaphor is not just about pet wellness as the Company is also involved in livestock health and productivity enhancement. In particular, Chemaphor is developing a line of feed additives, specifically for the poultry, swine and, potentially, fish producers. Revenue contribution is expected in about four years, which is about the timeline required to receive necessary government approvals.

Chemaphor is on the brink of profitability and its transition towards achieving a positive “net earnings” status is being driven by the initiation of revenue from its pet-wellness products and orchestrated by the experienced executive talent recently hired from the animal health market industry. This is supported by the growing number of dogs and cats as companion pets, the concomitant growth in the natural-health market for pets, and the equally increasing importance of veterinarian clinics as a pet-wellness distribution network. Chemaphor is leveraging off all three of these growth drivers.